MA51614A - Polythérapie pour le traitement ou la prévention du cancer - Google Patents
Polythérapie pour le traitement ou la prévention du cancerInfo
- Publication number
- MA51614A MA51614A MA051614A MA51614A MA51614A MA 51614 A MA51614 A MA 51614A MA 051614 A MA051614 A MA 051614A MA 51614 A MA51614 A MA 51614A MA 51614 A MA51614 A MA 51614A
- Authority
- MA
- Morocco
- Prior art keywords
- polytherapy
- cancer
- prevention
- treatment
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/42—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum viral
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A61K2039/507—Comprising a combination of two or more separate antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Microbiology (AREA)
- Organic Chemistry (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biochemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Virology (AREA)
- Biomedical Technology (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB1800927.4A GB201800927D0 (en) | 2018-01-19 | 2018-01-19 | Combination therapy for treating or preventing cancer |
GBGB1801502.4A GB201801502D0 (en) | 2018-01-30 | 2018-01-30 | Combination therapy for treating or preventing cancer |
GBGB1805941.0A GB201805941D0 (en) | 2018-04-10 | 2018-04-10 | Combination therapy for treating or preventing cancer |
GBGB1806572.2A GB201806572D0 (en) | 2018-04-23 | 2018-04-23 | Combination therapy for treating or preventing cancer |
GBGB1808636.3A GB201808636D0 (en) | 2018-05-25 | 2018-05-25 | Combination therapy for treating or preventing cancer |
Publications (1)
Publication Number | Publication Date |
---|---|
MA51614A true MA51614A (fr) | 2021-04-28 |
Family
ID=65278397
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MA051614A MA51614A (fr) | 2018-01-19 | 2019-01-18 | Polythérapie pour le traitement ou la prévention du cancer |
Country Status (14)
Country | Link |
---|---|
US (1) | US20210060093A1 (fr) |
EP (1) | EP3740219A1 (fr) |
JP (1) | JP2021510688A (fr) |
KR (1) | KR20200110341A (fr) |
CN (1) | CN111629740A (fr) |
AU (1) | AU2019210003A1 (fr) |
BR (1) | BR112020014595A2 (fr) |
CA (1) | CA3088333A1 (fr) |
IL (1) | IL275860A (fr) |
MA (1) | MA51614A (fr) |
MX (1) | MX2020007681A (fr) |
SG (1) | SG11202006870XA (fr) |
TW (1) | TW201938179A (fr) |
WO (1) | WO2019141997A1 (fr) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2023072968A1 (fr) * | 2021-10-25 | 2023-05-04 | 4D Pharma Research Ltd | Compositions comprenant des souches bactériennes |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB0127916D0 (en) | 2001-11-21 | 2002-01-16 | Rowett Res Inst | Method |
ES2895666T3 (es) | 2006-10-27 | 2022-02-22 | Capsugel Belgium Nv | Cápsulas duras de hidroxipropilmetilcelulosa y proceso de fabricación |
GB201112091D0 (en) | 2011-07-14 | 2011-08-31 | Gt Biolog Ltd | Bacterial strains isolated from pigs |
GB201117313D0 (en) | 2011-10-07 | 2011-11-16 | Gt Biolog Ltd | Bacterium for use in medicine |
GB201306536D0 (en) | 2013-04-10 | 2013-05-22 | Gt Biolog Ltd | Polypeptide and immune modulation |
WO2016196605A1 (fr) * | 2015-06-01 | 2016-12-08 | The University Of Chicago | Traitement du cancer par manipulation de la flore microbienne commensale |
MA41013A (fr) * | 2015-11-20 | 2017-08-30 | 4D Pharma Res Ltd | Compositions comprenant des souches bactériennes |
WO2018215782A1 (fr) * | 2017-05-24 | 2018-11-29 | 4D Pharma Research Limited | Compositions comprenant des souches bactériennes |
-
2019
- 2019-01-18 CN CN201980009131.7A patent/CN111629740A/zh active Pending
- 2019-01-18 MX MX2020007681A patent/MX2020007681A/es unknown
- 2019-01-18 KR KR1020207021004A patent/KR20200110341A/ko active Search and Examination
- 2019-01-18 MA MA051614A patent/MA51614A/fr unknown
- 2019-01-18 EP EP19703178.4A patent/EP3740219A1/fr active Pending
- 2019-01-18 AU AU2019210003A patent/AU2019210003A1/en not_active Abandoned
- 2019-01-18 BR BR112020014595-5A patent/BR112020014595A2/pt not_active IP Right Cessation
- 2019-01-18 JP JP2020537606A patent/JP2021510688A/ja active Pending
- 2019-01-18 WO PCT/GB2019/050142 patent/WO2019141997A1/fr active Application Filing
- 2019-01-18 CA CA3088333A patent/CA3088333A1/fr active Pending
- 2019-01-18 SG SG11202006870XA patent/SG11202006870XA/en unknown
- 2019-01-18 TW TW108101920A patent/TW201938179A/zh unknown
-
2020
- 2020-07-05 IL IL275860A patent/IL275860A/en unknown
- 2020-07-16 US US16/931,110 patent/US20210060093A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
CA3088333A1 (fr) | 2019-07-25 |
TW201938179A (zh) | 2019-10-01 |
BR112020014595A2 (pt) | 2020-12-08 |
IL275860A (en) | 2020-08-31 |
SG11202006870XA (en) | 2020-08-28 |
MX2020007681A (es) | 2020-09-14 |
JP2021510688A (ja) | 2021-04-30 |
EP3740219A1 (fr) | 2020-11-25 |
CN111629740A (zh) | 2020-09-04 |
AU2019210003A1 (en) | 2020-07-30 |
US20210060093A1 (en) | 2021-03-04 |
WO2019141997A1 (fr) | 2019-07-25 |
KR20200110341A (ko) | 2020-09-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MA49144A (fr) | Polythérapies pour le traitement du cancer | |
MA43746A (fr) | Dérivés de 2-cyanoisoindoline pour le traitement du cancer | |
MA45037A (fr) | Polythérapie à base d'arnm pour le traitement du cancer | |
MA45539A (fr) | Dihydropyranopyrimidines pour le traitement d'infections virales | |
MA55697A (fr) | Molécules d'anticorps pour le traitement du cancer | |
MA45192A (fr) | Traitement d'association | |
MA51613A (fr) | Polythérapie pour le traitement ou la prévention du cancer | |
MA48637A (fr) | Polythérapies pour le traitement du cancer | |
MA45146A (fr) | Dérivés de pyrazolopyridine pour le traitement du cancer | |
MA50409A (fr) | Polythérapies pour le traitement du cancer | |
MA47719A (fr) | Esketamine pour le traitement de la dépression | |
MA45481A (fr) | Utilisation d'exosomes pour le traitement de maladies | |
MA43000A (fr) | Polythérapie pour le traitement de tumeurs malignes | |
MA51139A (fr) | Dérivés de 1-(pipéridinocarbonylméthyl)-2-oxopipérazine pour le traitement du cancer | |
MA47604A (fr) | Anticorps anti-pd-1 pour le traitement du cancer du poumon | |
MA45429A (fr) | Polythérapie pour le traitement du cancer | |
MA41555A (fr) | Polythérapie pour le traitement du cancer | |
MA54925A (fr) | Compositions pour le traitement de troubles acido-basiques | |
MA42999A (fr) | Polythérapie pour le traitement de malignités | |
MA50943A (fr) | Anticorps anti-liv1 humanisés pour le traitement du cancer du sein | |
MA43170A (fr) | Association d'un inhibiteur de bcl-2 et d'un inhibiteur de mek pour le traitement du cancer | |
MA52627A (fr) | Traitement du cancer | |
MA43825A (fr) | Schémas posologiques pour le traitement d'infections fongiques | |
MA53873A (fr) | Compositions et procédés pour le traitement de la presbytie | |
MA54077A (fr) | Polythérapie pour le traitement de maladies hématologiques |